Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Gottlieb Worries Vaccine Policy Could Spark Federalism Debate

Mar 08 2019

• By Derrick Gingery

Infectious disease

Related Content

Opioid Packaging: Is Non-Inferiority Enough For A New Claim?

Dec 12 2017

US Enforcement 2019: Compounding, Opioids Top Priorities But Beware Of REMS Violations, Too

Dec 19 2018

Gottlieb: Real Risk Of Congressional Action If Anti-Competitive Actions Continue

May 04 2018

Sanofi's Dengvaxia Postmarket Monitoring Plan Targets Vaccine's Safety Concerns

Mar 06 2019

Gottlieb's Short Tenure Will Be Felt Long After He Leaves US FDA

Mar 06 2019

Sanofi’s Dengvaxia: US FDA Panel Finds Pediatric Use More Acceptable Than Broader Target Population

Mar 08 2019

Policy Reversal: FDA Will No Longer Require Suffixes For Older Biologics

Mar 07 2019

Gottlieb Wants His US FDA Team To Stay Together After He Departs

Mar 07 2019

Related Companies

Sanofi

Additional Topics

United States Vaccines Regulation FDA Infectious Diseases BioPharmaceutical

More from Vaccines

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window